Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2018 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly Income from Continuing Operations of 1006000.0 in Q3 2025, up 39.83% quarter-over-quarter from 1672000.0 in Q2 2025, and up 10.82% on a YoY basis from 907814.4 in Q3 2024.
Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 1006000.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations rose 10.82% year-over-year to 1006000.0; the TTM figure through Sep 2025 stood at 3633000.0 (up 38.68% YoY), while the FY2024 annual figure was 3628000.0, up 71.99% from the prior year.
- Income from Continuing Operations was 1006000.0 for Q3 2025 at Cyclerion Therapeutics, up from 1672000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 502000.0 in Q4 2024 to a low of 16176000.0 in Q2 2021.
- Historically, Income from Continuing Operations has averaged 5857736.84 across 5 years, with a median of 3275000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 33.13% in 2023, then soared 127.97% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 14338000.0 in 2021, then jumped by 68.93% to 4455000.0 in 2022, then jumped by 59.71% to 1795000.0 in 2023, then jumped by 127.97% to 502000.0 in 2024, then slumped by 300.4% to 1006000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 1006000.0 (Q3 2025), 1672000.0 (Q2 2025), and 1457000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | 502,000.00 |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -6.02 Mn |
| Jun 30, 2023 | -1.87 Mn |
| Mar 31, 2023 | -3.28 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -4.52 Mn |
| Jun 30, 2022 | -13.43 Mn |
| Mar 31, 2022 | -12.98 Mn |
| Dec 31, 2021 | -14.34 Mn |
| Sep 30, 2021 | -11.29 Mn |
| Jun 30, 2021 | -16.18 Mn |
| Mar 31, 2021 | -13.40 Mn |
| Dec 31, 2020 | -19.23 Mn |